Greg Tourangeau - Mar 8, 2024 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role: Vice President, Finance
Signature: /s/ Gregory Tourangeau
Stock symbol: FULC
Transactions as of: Mar 8, 2024
Transactions value $: -$57,219
Form type: 4
Date filed: 3/8/2024, 06:05 PM
Previous filing: Jan 30, 2024
Next filing: May 9, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FULC	Common Stock	Sale	-$57.2K	-4.88K	-29.26%	$11.72	11.8K	Mar 8, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.71 to $11.74, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
F2	Includes 699 shares acquired under the Issuer's employee stock purchase plan on May 13, 2022.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.71 to $11.74, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

Includes 699 shares acquired under the Issuer's employee stock purchase plan on May 13, 2022.